COGT
Next earnings: Aug 4, 2026 · Before open
Signal
Bearish Setup2
Price
1
Move-4.42%Selling pressure
Volume
1
Volume1.0× avgNormal activity
Technical
1
RSIRSI 39Momentum negative
PRICE
Prev Close
34.19
Open
33.85
Day Range32.46 – 34.27
32.46
34.27
52W Range4.55 – 43.73
4.55
43.73
72% of range
VOLUME & SIZE
Avg Volume
2.0M
FUNDAMENTALS
P/E Ratio
-15.1x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
0.52
Low vol
Performance
1D
-4.42%
5D
-6.47%
1M
-10.02%
3M
-10.54%
6M
-2.56%
YTD
-8.00%
1Y
+585.12%
Best: 1Y (+585.12%)Worst: 3M (-10.54%)
Quick Read
TrendInsufficient MA data
Momentum
BEARISH
thin 0% gross margin
Valuation
FAIR
P/E not available
Health
MODERATE
CR 15.1 · FCF negative
Neutral
Key MetricsTTM
Market Cap$5.58B
Revenue TTM$0.00
Net Income TTM-$354.30M
Free Cash Flow-$286.27M
Gross Margin0.0%
Net Margin0.0%
Operating Margin0.0%
Return on Equity-83.3%
Return on Assets-39.2%
Debt / Equity0.39
Current Ratio15.14
EPS TTM$-5.26

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
3 strong3 concern
48/100
Liquidity
15.14Strong
Leverage
0.39Strong
Coverage
-84.7xConcern
ROE
-83.3%Concern
ROIC
-42.8%Concern
Cash
$312MStrong
ANALYST COVERAGE12 analysts
BUY
+59.1%upside to target
L $35.00
Med $52.00consensus
H $60.00
Buy
1083%
Hold
217%
10 Buy (83%)2 Hold (17%)0 Sell (0%)
Full report →
Stock Health
Composite Score
2 of 5 signals bullish
3/10
Technicals
RSI RangeRSI 39 — Bearish momentum
Volume
Volume FlowDistribution — institutional selling
Fundamentals
Last EarningsMissed estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 15.14 — healthy liquidity
Upcoming Events
EEarnings ReportMay 17, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 90 days
PDividend PaymentAug 31, 2026
In 107 days
Technicals
Technical SetupBEARISH
Technicals →

Trend

PullbackGolden Cross · 50D leads 200D by 25.8%

-8.9% vs SMA 50 · +14.6% vs SMA 200

Momentum

RSI38.8
Momentum fading
MACD-0.57
Below zero — bearish pulse · compressing
Market Position
Price Levels
52W High
$43.73+33.8%
EMA 50
$35.82+9.6%
Current
$32.68
EMA 200
$27.26-16.6%
52W Low
$4.55-86.1%
52-Week RangeMid-range
$4.5572th %ile$43.73
Squeeze SetupVolume-based
Distribution Pressure

Distribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.

20-Day Money Flow
Acc days:0
Dist days:1
Edge:+1 dist
Volume Context
Avg Vol (50D)2.1M
Recent Vol (5D)
1.4M-34%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 9 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$1.5M
$461302$3.3M
-$2.27
±11%
High9
FY2026(current)
$11.2M
$5.6M$22.6M
+641.7%-$2.24
±14%
High9
FY2027
$348.3M
$102.2M$752.1M
+3001.5%-$0.77
±50%
High9
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryCOGT
Last 8Q
+8.9%avg beat
Beat 4 of 8 quartersMissed 3 Estimates rising
-7%
Q3'24
-16%
Q4'24
+85%
Q1'25
+7%
Q2'25
+4%
Q3'25
+7%
Q4'25
-8%
Q1'26
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
No recent activity
WedbushOutperform
Nov 10
UPGRADE
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
Fairmount Funds Man…Dir
$242.6M
Mar 31
SELL
Fairmount Funds Man…Dir
$127.4M
Jan 22
SELL
Kearns EvanChief Legal Of…
$2.5M
Dec 26
SELL
Green John L.CFO
$3.0M
Dec 26
SELL
Sachs JessicaChief Medical …
$3.2M
Dec 26
SELL
Robinson John EdwardChief Scientif…
$3.5M
Dec 26
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
FMR LLC
23.1M
2
BlackRock, Inc.
16.0M
3
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
9.0M
4
JANUS HENDERSON GROUP PLC
6.0M
5
STATE STREET CORP
5.7M
6
Fairmount Funds Management LLC
5.5M
7
RTW INVESTMENTS, LP
5.5M
8
TCG Crossover Management, LLC
4.9M
News & Activity

COGT News

About

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent Biosciences is headquartered in Cambridge, MA.

Industry
Pharmaceutical Preparation Manufacturing
Rachael EastonSenior Vice President of Clinical Development
Abb HaydenSenior Vice President of Sales
Andrew R. RobbinsPresident, Chief Executive Officer & Director
PeersHealth Care(7 companies)
Screen sector →
SymbolPriceDay %Mkt CapP/ERev GrwMarginELO
COGT
$32.68-4.42%$5.6B1500
$66.13-5.07%$13.0B+12626.1%-14525.8%1500
$94.92-3.79%$12.6B+3288.2%-4239.0%1500
$523.69-3.00%$12.1B+43205.3%-3008.0%1500
$227.72-1.30%$11.7B+6554.5%-2868.8%1500
$57.90-0.86%$11.2B50.3+1459.3%147.7%1500
$76.67-3.79%$10.8B+2325815.3%-19.7%1500
Sector avg-3.17%50.3+398824.8%-4085.6%1500